11 assets in Endometrial Clear Cell Adenocarcinoma

Therapeutic assets addressing Endometrial Clear Cell Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Endometrial Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Lorigerlimab Endometrial Clear Cell Adenocarcinoma	MacroGenics	P2	CCC (53)
Nivolumab Endometrial Clear Cell Adenocarcinoma	Instituto do Cancer do Estado de São Paulo	P2	CCC (53)
Valemetostat Endometrial Clear Cell Adenocarcinoma	Gustave Roussy, Cancer Campus, Grand Paris	P2	CCC (53)
Pasifolate Exatecan Endometrial Clear Cell Adenocarcinoma	Elucida Oncology	P1/2	CCC (48)
Amt-151 Endometrial Clear Cell Adenocarcinoma	Multitude Therapeutics Inc.	P1	CC (43)
Atezolizumab Endometrial Clear Cell Adenocarcinoma	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Bet Bromodomain Inhibitor Zen-3694 Endometrial Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (43)
Sapanisertib Endometrial Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (43)
Tuvusertib Endometrial Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (43)
Dordaviprone Endometrial Clear Cell Adenocarcinoma	UNC Lineberger Comprehensive Cancer Center	P1	C (39)